Whitefort Capital Management LP Invests $15.14 Million in Surgery Partners, Inc. $SGRY

Whitefort Capital Management LP bought a new stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 901,332 shares of the company's stock, valued at approximately $15,142,378. Surgery Partners accounts for about 0.0% of Whitefort Capital Management LP's investment portfolio, making the stock its 12th biggest holding. Whitefort Capital Management LP owned approximately 0.69% of Surgery Partners as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. UBS Group AG raised its stake in Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company's stock valued at $120,571,000 after acquiring an additional 4,113,052 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Surgery Partners by 7.9% in the first quarter. Dimensional Fund Advisors LP now owns 5,296,411 shares of the company's stock valued at $63,131,000 after purchasing an additional 389,831 shares in the last quarter. Irenic Capital Management LP increased its position in shares of Surgery Partners by 740.2% during the first quarter. Irenic Capital Management LP now owns 711,000 shares of the company's stock worth $8,475,000 after acquiring an additional 626,380 shares during the period. Hsbc Holdings PLC increased its holdings in shares of Surgery Partners by 104.2% during the fourth quarter. Hsbc Holdings PLC now owns 1,931,577 shares of the company's stock valued at $30,151,000 after acquiring an additional 985,748 shares in the last quarter. Finally, Clearline Capital LP acquired a new position in Surgery Partners during the fourth quarter worth $3,088,000.

Insider Buying and Selling

In related news, Director Teresa Deluca bought 10,000 shares of the company's stock in a transaction on Tuesday, August 18th. The stock was bought at an average cost of $14.35 per share, with a total value of $143,500.00. Following the completion of the purchase, the director owned 66,843 shares in the company, valued at approximately $959,197.05. The trade was a 17.59% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SGRY has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a "buy" rating and issued a $17.00 target price on shares of Surgery Partners in a report on Wednesday, May 6th. Zacks Research lowered shares of Surgery Partners from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $18.00 price target on shares of Surgery Partners in a research note on Tuesday, August 11th. Raymond James Financial set a $18.00 target price on shares of Surgery Partners in a research report on Tuesday, August 11th. Finally, TD Cowen raised their price objective on shares of Surgery Partners from $17.00 to $19.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $19.45.

Surgery Partners Stock Performance

Shares of NASDAQ:SGRY traded down $0.29 during trading on Friday, hitting $13.64. 758,890 shares of the stock traded hands, compared to its average volume of 1,627,193. Surgery Partners, Inc. has a 52-week low of $11.41 and a 52-week high of $23.44. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 1.18. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -19.49, a P/E/G ratio of 4.33 and a beta of 1.91. The company has a fifty day moving average price of $15.51 and a two-hundred day moving average price of $14.39.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.06 by $0.04. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. The firm had revenue of $848.90 million during the quarter, compared to the consensus estimate of $830.03 million. During the same quarter in the prior year, the firm earned $0.17 EPS. Surgery Partners's revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities analysts predict that Surgery Partners, Inc. will post 0.22 EPS for the current year.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.